The Moscow Region Commercial Court has ordered pharmaceutical companies ViiV Healthcare and Shionogi to grant Biokhimik, part of the Promomed Group, a non-exclusive licence covering two Eurasian patents and one Russian national patent related to cabotegravir. According to Pharmvestnik, the ruling was issued on 20 October 2026. It has not yet entered into force and may be appealed within one

September 3, twenty-five patient organizations working in the field of HIV response in Russia published an open letter to Gilead Sciences, asking the pharmaceutical company to disclaim patent rights for the combination of tenofovir and emtricitabine, marketed under the tradename Truvada.